Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, UK.
The Park Medical Practice, Shepton Mallet, UK.
Int J Chron Obstruct Pulmon Dis. 2021 Nov 1;16:3009-3016. doi: 10.2147/COPD.S329316. eCollection 2021.
Therapeutic inertia, defined as failure to escalate or initiate adequate therapy when treatment goals are not met, contributes to poor management of COPD exacerbations.
A multidisciplinary panel of five expert clinicians actively managing COPD and representative of UK practice developed action points to reduce exacerbation risk, based on evidence, clinical expertise, and experience. The action points are applicable despite changing circumstances (eg, virtual clinics). The panel agreed areas where further evidence is needed.
The four action points were (1) an experienced HCP, such as a GP or member of the multi-professional COPD team should review patients within one month of every exacerbation that requires oral steroids, antibiotics, or hospitalization to address modifiable risk factors, optimize non-pharmacological measures, and evaluate pharmacological therapy. (2) Presenting to hospital with an exacerbation defines an important window of opportunity to reduce the risk of further exacerbations. Follow-up by a GP, or member of the multi-professional specialist COPD team within one month of discharge with a full management review and appropriate escalation of pharmacological treatment is essential. (3) Healthcare professionals (HCPs) in all healthcare settings should be able to recognize COPD exacerbations, refer as appropriate and document the episode accurately in medical records across service boundaries. HCPs should support patients to recognize and report exacerbations. (4) HCPs should intervene proactively based on risk assessments, disease activity and any treatable traits at or as soon as possible after diagnosis and annually thereafter. Delivering these action points needs coordinated action with policymakers, funders, and service providers.
These action points should be a fundamental part of clinical practice to determine if a change in management is necessary to reduce the risk of exacerbations. Policymakers should use these action points to develop systems and initiatives that reduce the risk of further exacerbations.
治疗惰性是指在未达到治疗目标时未能升级或启动足够的治疗,这导致 COPD 加重的管理不善。
一个由五名精通 COPD 管理的多学科专家临床医生组成的小组,代表了英国的实践经验,根据证据、临床专业知识和经验制定了降低加重风险的行动要点。这些行动要点适用于不断变化的情况(例如,虚拟诊所)。小组同意需要进一步证据的领域。
四个行动要点是:(1)在需要口服类固醇、抗生素或住院治疗的每次加重后一个月内,应由经验丰富的医疗保健提供者(如全科医生或多专业 COPD 团队成员)审查患者,以解决可改变的危险因素,优化非药物措施,并评估药物治疗。(2)因加重而就诊医院定义了降低进一步加重风险的重要机会窗口。在出院后一个月内,应由全科医生或多专业 COPD 团队成员进行随访,进行全面管理审查并适当升级药物治疗至关重要。(3)所有医疗保健环境中的医疗保健专业人员(HCPs)都应能够识别 COPD 加重,根据需要进行转诊,并在医疗记录中准确记录发作情况,跨越服务边界。HCP 应支持患者识别和报告加重。(4)HCP 应根据风险评估、疾病活动度和任何可治疗的特征,在诊断时或尽快开始并在随后的每年进行主动干预。实施这些行动要点需要与政策制定者、资金提供者和服务提供商协调行动。
这些行动要点应成为临床实践的基础,以确定是否需要改变管理以降低加重风险。政策制定者应使用这些行动要点制定系统和计划,以降低进一步加重的风险。